Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Immunic (IMUX) been one of those stocks this year? A quick glance at the company ...
Immunic (IMUX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...
) has been revised to $5.48 / share. This is a decrease of 14.49% from the prior estimate of $6.41 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...
The average one-year price target for Immunic (NASDAQ:IMUX) has been revised to 17.00 / share. This is an increase of 25.79% from the prior estimate of 13.52 dated October 4, 2023. The price target is ...
Immunic (IMUX) announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, has been published in the ...
Key Insights Significant control over Immunic by retail investors implies that the general public has more power to... Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback